- Home
- ALT
ALT
Altimmune Inc.
as 03-28-2025 3:30pm EST
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 472.3M | IPO Year: | N/A |
| Target Price: | $21.00 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.14 - $11.16 | Next Earning Date: | 05-08-2025 |
| Revenue: | $20,000 | Revenue Growth: | -95.31% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Altimmune Inc. (ALT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sohn Catherine A. | ALT | Director | Mar 17 '25 | Buy | $5.78 | 1,000 | $5,784.50 | 1,000 | |
| WEAVER GREGORY L | ALT | Chief Financial Officer | Mar 13 '25 | Buy | $5.20 | 10,000 | $51,996.00 | 10,000 |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
22 days ago
Altimmune to Host Virtual R&D Day on March 13, 2025
GlobeNewswire
25 days ago
Altimmune to Participate in the Leerink Global Healthcare Conference
Simply Wall St.
a month ago
Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
GlobeNewswire
a month ago
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
a month ago
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
GlobeNewswire
a month ago
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025
Simply Wall St.
2 months ago
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns
GlobeNewswire
2 months ago
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.